Aurobindo Pharma Ltd. | Large-cap | Healthcare
₹1,121.00
-0.20%
| Aurobindo Pharma Stock Comparison:
No comparison data available
Overview Income Statement Balance Sheet Cash Flow Key Ratios

Financial Overview

Latest Annual: 2025

Income Metrics

Revenue 313.8B
Gross Profit 183.5B 58.49%
Operating Income 49.6B 15.79%
Net Income 34.8B 11.10%

Balance Sheet Metrics

Total Assets 497.8B
Total Liabilities 171.4B
Shareholders Equity 326.5B
Debt to Equity 0.52

Cash Flow Metrics

Operating Cash Flow 41.5B
Free Cash Flow 14.1B

Revenue & Profitability Trend

Aurobindo Pharma Income Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Revenue 313.8B 287.0B 246.2B 233.7B 245.6B
Cost of Goods Sold 130.3B 132.4B 119.0B 108.2B 106.1B
Gross Profit 183.5B 154.7B 127.2B 125.5B 139.5B
Operating Expenses 76.2B 58.4B 55.2B 46.4B 49.7B
Operating Income 49.6B 43.9B 25.4B 33.0B 44.8B
Pre-tax Income 48.7B 43.8B 26.1B 33.7B 73.4B
Income Tax 15.8B 12.1B 6.8B 7.3B 20.1B
Net Income 34.8B 31.7B 19.3B 26.5B 53.3B
EPS (Diluted) - ₹54.16 ₹32.90 ₹45.19 ₹91.05

Income Statement Trend

Aurobindo Pharma Balance Sheet From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Assets
Current Assets 271.6B 242.1B 215.5B 181.2B 198.2B
Non-Current Assets 226.2B 208.7B 183.4B 158.0B 140.3B
Total Assets 497.8B 450.7B 398.9B 339.2B 338.5B
Liabilities
Current Liabilities 146.8B 122.0B 114.9B 81.6B 106.7B
Non-Current Liabilities 24.6B 30.2B 15.4B 11.9B 12.6B
Total Liabilities 171.4B 152.2B 130.4B 93.5B 119.2B
Equity
Total Shareholders Equity 326.5B 298.5B 268.5B 245.7B 219.3B

Balance Sheet Composition

Aurobindo Pharma Cash Flow Statement From 2021 to 2025

Metric 2025 2024 2023 2022 2021
Operating Activities
Net Income 50.7B 43.8B 26.1B 33.7B 73.4B
Operating Cash Flow 41.5B 20.0B 7.6B 48.2B 63.1B
Investing Activities
Capital Expenditures -19.7B -27.2B -23.9B -16.7B -13.9B
Investing Cash Flow -16.7B -37.6B -38.1B -25.9B 10.2B
Financing Activities
Dividends Paid -10.4M -2.6B -4.4B -2.6B -2.3B
Financing Cash Flow 6.5B 12.0B 20.2B -28.2B -18.6B
Free Cash Flow 14.1B -11.3B -3.3B 23.1B 14.6B

Cash Flow Trend

Aurobindo Pharma Key Financial Ratios

Valuation Ratios

P/E Ratio (TTM) 18.39
Forward P/E 17.65
Price to Book 1.96
Price to Sales 2.01
PEG Ratio 17.65

Profitability Ratios

Profit Margin 10.99%
Operating Margin 16.08%
Return on Equity 11.15%
Return on Assets 6.53%

Financial Health

Current Ratio 1.85
Debt to Equity 25.31
Beta 0.22

Per Share Data

EPS (TTM) ₹59.80
Book Value per Share ₹562.37
Revenue per Share ₹544.31

Financial data is updated regularly. All figures are in the company's reporting currency.